Press Releases

Date Title View
Toggle Summary Second Sight to Present at the 11th Annual LD Micro Main Event Conference in Los Angeles on Wednesday, December 5th
LOS ANGELES , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today
View HTML
Toggle Summary Second Sight Reports Third Quarter 2018 Financial Results
Encouraging Interim Results of Orion ® Feasibility Study with Four Subjects Cleared for Home Use LOS ANGELES , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual
View HTML
Toggle Summary Second Sight Announces Final 2019 Medicare Hospital Outpatient Payment Rate for the Argus II Retinal Prosthesis System
LOS ANGELES , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Second Sight Medical Products , Inc. (NASDAQ:EYES) (“Second Sight” or the “Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today
View HTML
Toggle Summary Second Sight to Discuss Third Quarter 2018 Financial Results on November 7, 2018 Conference Call
LOS ANGELES --(BUSINESS WIRE)--Oct. 30, 2018-- Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, will release its 2018 third quarter
View HTML
Toggle Summary Second Sight Completes $4 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors
LOS ANGELES --(BUSINESS WIRE)--Oct. 22, 2018-- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind individuals, today
View HTML
Toggle Summary Second Sight Receives $1.6 Million Grant from National Institutes of Health to Support Orion Clinical Development
--Total Grant Amount Up to $6.3 Million Over Five Years-- LOS ANGELES --(BUSINESS WIRE)--Sep. 18, 2018-- Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an
View HTML
Toggle Summary Second Sight Appoints Pat Ryan Chief Operating Officer
SYLMAR, Calif. --(BUSINESS WIRE)--Sep. 4, 2018-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, announced
View HTML
Toggle Summary Second Sight to Present at Investor Conferences in September
LOS ANGELES --(BUSINESS WIRE)--Aug. 22, 2018-- Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today
View HTML
Toggle Summary Second Sight Completes $5.0 million Private Placement of Common Stock with Gregg Williams, Chairman of the Board of Directors
LOS ANGELES --(BUSINESS WIRE)--Aug. 16, 2018-- Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision to blind patients, today
View HTML
Toggle Summary Second Sight Reports Second Quarter 2018 Financial Results
-- Achieves program milestones as Orion clinical and R&D activities advance -- -- Received FDA approval to enroll 6 th patient at Baylor -- LOS ANGELES --(BUSINESS WIRE)--Aug. 7, 2018-- Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer
View HTML